Your IND is ready when FDA reviewers can trace a defensible line from product quality and nonclinical evidence to the proposed starting dose, clinical safeguards, and sponsor controls. Document volume doesn’t establish readiness; phase-appropriate evidence that supports a safe decision does.
This 12-point IND submission checklist is written for biotech sponsors, regulatory leads, CMC teams, and sponsor-investigators preparing an initial FDA filing. You’ll learn how to test the application as a connected safety case, catch contradictions before publishing, and prepare for questions during the 30-day review period. The standard is simple: every major claim must be supported, consistent, and usable by a reviewer.
Checklist Point 1: Confirm the Regulatory Route and FDA Review Center
Begin by confirming that the proposed clinical investigation requires an IND and that you’re approaching the correct FDA center. Some studies of lawfully marketed drugs may qualify for an IND exemption, but the study must meet every applicable condition; FDA’s IND exemption decision tree helps sponsors assess those criteria. A drug-led combination product can add a center-assignment question, particularly when its primary mode of action or product classification isn’t settled. Resolve that question early enough to shape your testing plan, submission format, and agency interactions.
Create one controlled product description that states the active ingredient or biological material, dosage form, route, indication, target population, and proposed study phase. Use the same terminology in Form FDA 1571, the cover letter, general investigational plan, CMC section, nonclinical summaries, protocol, and investigator’s brochure. If the product name, formulation, route, or sponsor identity changes between documents, the reviewer must spend time determining which version governs. A sponsor located outside the United States should also confirm the U.S. representative and countersignature requirements stated in 21 CFR 312.23.
Checklist Point 2: Close Every Pre-IND Meeting Commitment
A pre-IND meeting isn’t mandatory, but it can resolve questions that would otherwise affect the nonclinical program, CMC package, or first clinical protocol. For CBER-regulated products, FDA describes the meeting as a way to obtain feedback on the studies, manufacturing controls, and clinical design needed to support an IND; CDER also offers early consultation through its review divisions. Use it when your modality, starting-dose method, toxicology plan, manufacturing strategy, or clinical design presents a question that guidance doesn’t settle for your product. The value comes from targeted agency questions, not from presenting a broad company update.
Turn the meeting record into a decision log with five fields: FDA feedback, sponsor interpretation, affected documents, accountable owner, and closure evidence. Check each commitment against the filed version, including any testing promised after the meeting and before submission. If your team chose a different path, explain the scientific basis and identify the change rather than leaving the reviewer to discover it. FDA’s draft formal-meeting guidance covers meeting requests, packages, formats, and follow-up records for CDER- and CBER-regulated products.
Checklist Point 3: Complete the Administrative Backbone
The administrative package tells FDA what you’re submitting, who accepts sponsor responsibility, and how the application is organized. Under 21 CFR 312.23, the ordered content begins with Form FDA 1571, a table of contents, and the introductory statement and general investigational plan. Review the current FDA forms and instructions, then confirm signatures, addresses, phase designation, monitoring responsibility, safety-review responsibility, and any transferred CRO obligations. Include applicable certifications, letters of authorization, cross-references, environmental documentation, and accurate English translations.
Don’t add a form merely because it appears on an FDA forms page. The required set depends on the sponsor type, product, study, information incorporated by reference, and filing route. FDA notes in its IND application procedures that clinical-investigator financial information isn’t required in an original IND, and its informed-consent guidance says the IND regulations don’t routinely require a consent form in the initial filing; FDA can request it when needed for review. A controlled document index should show each required item, its owner, approval state, eCTD location, effective date, and source record.
Checklist Point 4: Make the General Investigational Plan a Reviewer Roadmap
Your introductory statement and general investigational plan should let a reviewer understand the product and the coming year without reconstructing the program from separate modules. The regulation calls for the active ingredients, pharmacological class, known structure, dosage form, route, objectives, planned duration, previous human experience, and a brief one-year development plan. It also asks for the rationale, indication, trial types, estimated participant count, and serious risks anticipated from animal or prior human evidence. Treat this section as a precise map to the application, not as promotional copy.
State what is known, what remains uncertain, and how the proposed trial controls each material uncertainty. Summarize prior human use in the United States or other countries, including relevant investigational or marketing experience and any safety-related withdrawal. Make direct cross-references to the supporting CMC, nonclinical, and clinical documents so the reviewer can verify each claim. If a first-year study remains undecided, say so rather than presenting a tentative plan as approved internally.
Checklist Point 5: Keep the CMC Package Phase-Appropriate
Your CMC section must establish the identity, quality, purity, strength, and stability of the material used in the proposed trial. It doesn’t need to resemble a commercial marketing application at first-in-human stage. FDA states that the amount of CMC information depends on the study phase, formulation, duration, and available product knowledge. The submission still needs enough information on the drug substance, drug product, manufacturing sites, production method, controls, analytical methods, specifications, stability, labeling, placebo when used, and environmental analysis to assess risk.
Match detail to the product and study rather than filling every possible heading with low-value text. In June 2026, FDA clarified CMC flexibilities for certain original first-in-human Phase 1 INDs, noting that full analytical-method validation and process controls unrelated to product safety aren’t expected in the covered cases. The same FDA page explains that clinical-lot stability data or stability covering the full study period may not always be needed under its stated conditions. Apply the product-specific guidance carefully; a flexibility for a CDER-regulated small molecule or recombinant biological product shouldn’t be carried over to another modality without support.
Checklist Point 6: Link the Clinical Lot, Toxicology Lot, and Manufacturing History
FDA must be able to determine whether the nonclinical evidence supports exposure to the material participants will receive. That assessment becomes harder when the toxicology lot and clinical lot differ in process, scale, formulation, specifications, impurities, potency, container closure, or storage. A difference isn’t automatically disqualifying, but it needs a scientific bridge proportionate to its possible effect on safety and product performance. Unexplained manufacturing changes can weaken an otherwise adequate pharmacology and toxicology package.
Build a lot-use table listing each material’s batch number, manufacturing site, process version, scale, release results, impurity profile, stability status, and use in nonclinical or clinical work. Add a change history that records what changed, why it changed, the risk assessment, and the data supporting comparability. Check that certificates of analysis and summary tables agree with source records and Module 3 descriptions. If a supporting study report identifies one lot and the CMC narrative identifies another, resolve the discrepancy before publishing the sequence.
Checklist Point 7: Show That Nonclinical Evidence Supports the Proposed Exposure
Your nonclinical package should support the proposed population, route, starting dose, escalation plan, treatment duration, and clinical monitoring. 21 CFR 312.23 requires adequate pharmacology and toxicology information to support a conclusion that the proposed investigation is reasonably safe to conduct. The needed studies depend on the product, indication, trial design, and duration. A collection of completed reports isn’t enough if the integrated assessment never connects their findings to the clinical protocol.
Explain pharmacologic activity, exposure, disposition when known, target-organ findings, dose response, reversibility, and the relevance of the tested species or other model. Identify GLP status, material deviations, study limitations, and unresolved safety signals without burying them in appendices. Your starting-dose rationale should connect the selected method, nonclinical exposure, pharmacology, safety factors, and planned escalation controls; FDA’s first-in-human starting-dose guidance describes the maximum recommended starting-dose method for adult healthy-volunteer trials. Products with complex biology may require another justified method, so the calculation must fit the molecule and intended participants.
Checklist Point 8: Write the Protocol Around Identified Risks
The protocol must convert known and plausible risks into eligibility rules, dosing controls, monitoring, stopping criteria, and follow-up. Phase 1 protocols can retain operational flexibility, yet FDA expects detail for elements that protect participants. The regulation specifically addresses study objectives, investigator and facility information, participant selection, design, dose determination, exposure duration, observations, laboratory tests, and measures that reduce risk. Review every protocol control against the CMC, nonclinical, and prior human findings that justify it.
Define dose preparation and administration, sentinel or staggered dosing when warranted, escalation decisions, dose-limiting toxicity rules, stopping rules, rescue measures, safety-review timing, and follow-up. Make the maximum planned exposure traceable to the evidence used in your starting-dose and escalation rationale. FDA’s clinical-hold examples include inadequate nonclinical support for a dosing regimen, failure to monitor previously observed toxicity, and simultaneous dosing where an unpredictable acute reaction calls for added protection. A protocol that acknowledges a risk but provides no operational response leaves the safety case unfinished.
Checklist Point 9: Align the Investigator’s Brochure, Protocol, and Risk Documents
The investigator’s brochure should give investigators a current, balanced account of the product, nonclinical findings, prior human experience, expected risks, and required precautions. FDA’s content rule calls for summaries of pharmacology, toxicology, pharmacokinetics, biological disposition, human safety and effectiveness data, possible adverse effects, and special monitoring. The brochure isn’t a corporate profile or a shortened CMC dossier. It is the investigator’s working source for safe study conduct.
Create a risk-alignment table that compares each identified risk across the investigator’s brochure, protocol, informed-consent materials, pharmacy instructions, monitoring plan, and submission summaries. Use consistent medical terms, severity descriptions, monitoring intervals, and management actions. FDA identifies a misleading, erroneous, or materially incomplete investigator’s brochure as a possible ground for a Phase 1 clinical hold. If a risk appears in toxicology but nowhere in the protocol or brochure, decide whether it needs a control or document why it doesn’t translate to the proposed study.
Checklist Point 10: Demonstrate That Sponsor Oversight Is Operational
An IND filing creates continuing sponsor duties, so the people and systems named in the application must already be able to perform them. Form FDA 1571 identifies who monitors study conduct and who reviews safety information; the filing must also describe duties transferred to a CRO. Confirm medical monitoring, pharmacovigilance, regulatory operations, clinical supplies, document control, vendor oversight, and escalation routes before submission. FDA information requests can arrive during the review window, and unclear ownership wastes response time.
Test the safety-reporting process using a sample event from intake through medical assessment, expectedness review, causality decision, investigator notification, and FDA transmission. FDA’s current IND safety-reporting page states that qualifying reports generally have a 15-calendar-day deadline, with a 7-calendar-day deadline for unexpected fatal or life-threatening suspected adverse reactions. It also states that, from April 1, 2026, specified commercial IND safety reports must use E2B(R3) data standards through FDA’s electronic safety system; noncommercial INDs are exempt from that electronic requirement. Keep IRB approval, site activation, investigator agreements, training, and product release on a coordinated start-up plan because an effective IND alone doesn’t authorize dosing at an unready site.
Checklist Point 11: Validate the eCTD Sequence Before Transmission
Commercial INDs must be submitted electronically in eCTD format, and FDA encourages the format for noncommercial INDs even where it remains optional. FDA currently supports eCTD v3.2.2 and v4.0 for new INDs, subject to the versions and dates in its standards catalog. The agency’s eCTD resource page identifies the supported standards, technical guides, validation criteria, and submission resources. Select the version and publishing plan before authoring is locked, since late remapping creates avoidable errors.
Run technical validation on sequence 000 and review every warning or error rather than relying on successful folder creation. Inspect metadata, headings, lifecycle operators, file formats, bookmarks, hyperlinks, leaf titles, study tags, cross-references, and PDF rendering. Confirm that linked files open, tables remain legible, signatures display, and no draft comments or tracked changes remain. Monitor the transmission pathway for FDA acknowledgments because a delivered package and an accepted technical sequence aren’t the same event.
Checklist Point 12: Run an Integrated Mock Review and Prepare for Day 1–30
The last readiness review should test the application through the questions an FDA reviewer must answer, not through departmental completion percentages. Can the reviewer identify the clinical material, understand how it was controlled, connect it to the toxicology material, verify the proposed exposure, locate each risk, and see the protocol response? Can the reviewer tell who owns safety review and how the sponsor will act on new information? FDA lists insufficient information to assess participant risk as a ground for a Phase 1 clinical hold, so unresolved cross-document gaps deserve the same attention as missing reports.
Submit with a response team, source records, and decision makers available throughout the review period. FDA’s IND application procedures say an IND may go into effect 30 calendar days after receipt unless the agency places the study on clinical hold, or earlier if FDA notifies the sponsor that the study may begin; this is not an approval of the product. Track every agency question, response, supporting record, affected document, and resulting commitment in one controlled log. Do not dose until the IND is in effect, the IRB has approved the study, and all applicable site and product-release conditions are satisfied.
What Does an Initial IND Submission Need?
- Form FDA 1571 and contents
- General investigational plan
- Investigator’s brochure
- Clinical protocol
- CMC information
- Pharmacology/toxicology data
- Prior human experience
- Safety and monitoring plans
- eCTD files for commercial INDs
A Ready IND Tells One Defensible Safety Story
Your IND readiness decision should come from evidence alignment, not document count. The product description, manufacturing record, nonclinical findings, starting dose, protocol controls, and investigator guidance must support the same proposed study. Phase-appropriate CMC prevents unnecessary work, but it doesn’t excuse gaps that block a product-quality assessment. A disciplined mock review exposes contradictions that separate functional teams can miss, and an active response plan keeps the 30-day review from becoming a scramble. When reviewers can follow every material risk to its evidence and control, your submission is ready to support a decision.
References
- U.S. Food and Drug Administration. Investigational New Drug Application: Exemptions from IND Requirements
- Electronic Code of Federal Regulations. 21 CFR 312.23: IND Content and Format
- U.S. Food and Drug Administration. Formal Meetings and Requests for Feedback for CBER-Regulated Products
- U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products
- U.S. Food and Drug Administration. IND Forms and Instructions
- U.S. Food and Drug Administration. IND Application Procedures: Overview
- U.S. Food and Drug Administration. Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors
- U.S. Food and Drug Administration. IND Applications: Chemistry, Manufacturing, and Control Information
- U.S. Food and Drug Administration. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
- U.S. Food and Drug Administration. IND Application Procedures: Clinical Hold
- U.S. Food and Drug Administration. IND Application Reporting: IND Safety Reports
- U.S. Food and Drug Administration. Electronic Common Technical Document (eCTD)